Cartesian Therapeutics, Inc. (RNAC)Healthcare | Biotechnology | Frederick, United States | NasdaqGM
6.58 USD
+0.24
(3.785%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 6.58 |
Hot Take ↕ | Oct. 10, 2026, 7:28 a.m. EDT
The investment case for Cartesian Therapeutics is currently broken by a catastrophic multi-year decline in share price. Over the last nine years, the stock has lost nearly 98% of its value, with the trailing four years showing consecutive negative annual returns. This is not merely a temporary correction; it reflects a deep structural deterioration where the market has priced out the company's prospects. Fundamentally, the business is bleeding cash with negative operating margins and no revenue growth, while the balance sheet shows negative book value. Although analysts project a significant recovery to the mid-$30s, this is a speculative bet on a future turnaround rather than a reflection of current operational reality. The options market confirms this pessimism, with traders loading up on puts to hedge against further drops. There is no dividend to provide income, and the recent price action remains under pressure. This is a high-risk speculative vehicle for those willing to gamble on a clinical trial success, but it fails every standard metric for a sound investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.111958 |
| AutoETS | 0.125799 |
| AutoARIMA | 0.125800 |
| MSTL | 0.126662 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 1.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.477 |
| Excess Kurtosis | -0.79 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.055 |
| Market Cap | 199,080,208 |
| Forward P/E | -1.73 |
| Beta | 0.72 |
| Website | https://www.cartesiantherapeutics.com |
As of Oct. 10, 2026, 7:28 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive put volume and open interest relative to calls in the near-to-intermediate term. While there is some call activity at strikes significantly above the current price, the overwhelming weight of capital is flowing into out-of-the-money puts, suggesting a consensus view of continued volatility and potential further declines rather than a catalyst-driven rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3269639 |
| Address1 | 7,495 New Horizon Way |
| All Time High | 840.0 |
| All Time Low | 5.6 |
| Ask | 10.59 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 168,860 |
| Average Daily Volume3 Month | 132,354 |
| Average Volume | 132,354 |
| Average Volume10Days | 168,860 |
| Beta | 0.721 |
| Bid | 5.98 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | -4.169 |
| City | Frederick |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.58 |
| Current Ratio | 7.475 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 6.7759 |
| Day Low | 6.39 |
| Display Name | Cartesian Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Growth | -0.08 |
| Earnings Quarterly Growth | -0.007 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -96,051,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.201 |
| Enterprise To Revenue | 78.082 |
| Enterprise Value | 115,327,216 |
| Eps Current Year | -2.78 |
| Eps Forward | -3.81 |
| Eps Trailing Twelve Months | -5.78 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.3685 |
| Fifty Day Average Change | -1.7884998 |
| Fifty Day Average Change Percent | -0.2137181 |
| Fifty Two Week Change Percent | -32.69639 |
| Fifty Two Week High | 11.0 |
| Fifty Two Week High Change | -4.42 |
| Fifty Two Week High Change Percent | -0.4018182 |
| Fifty Two Week Low | 5.6 |
| Fifty Two Week Low Change | 0.98 |
| Fifty Two Week Low Change Percent | 0.17500001 |
| Fifty Two Week Range | 5.6 - 11.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,466,602,200,000 |
| Float Shares | 11,488,562 |
| Forward Eps | -3.81 |
| Forward P E | -1.7270341 |
| Free Cashflow | -47,480,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 75 |
| Fullday Change | 0.23999977 |
| Fullday Change Percent | 3.7854853 |
| Fullday Price | 6.58 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -66,908,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.52133 |
| Held Percent Institutions | 0.29448998 |
| Implied Shares Outstanding | 30,255,352 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,712,275,200 |
| Last Split Factor | 1:30 |
| Long Business Summary | Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland. |
| Long Name | Cartesian Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 199,080,208 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_371375105 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -151,891,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 238,109,620 |
| Number Of Analyst Opinions | 6 |
| Open | 6.39 |
| Operating Cashflow | -76,529,000 |
| Operating Margins | -66.79689 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 301 348 8698 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.58 |
| Post Market Time | 1,792,094,506 |
| Previous Close | 6.34 |
| Price Eps Current Year | -2.3669064 |
| Price Hint | 2 |
| Price To Book | -1.5783161 |
| Price To Sales Trailing12 Months | 134.78687 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.192 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.24 |
| Regular Market Change Percent | 3.78549 |
| Regular Market Day High | 6.7759 |
| Regular Market Day Low | 6.39 |
| Regular Market Day Range | 6.39 - 6.7759 |
| Regular Market Open | 6.39 |
| Regular Market Previous Close | 6.34 |
| Regular Market Price | 6.58 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 86,765 |
| Return On Assets | -0.1743 |
| Revenue Per Share | 0.055 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 30,255,352 |
| Shares Percent Shares Out | 0.061300002 |
| Shares Short | 1,855,626 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,811,559 |
| Short Name | Cartesian Therapeutics, Inc. |
| Short Percent Of Float | 0.1337 |
| Short Ratio | 14.59 |
| Source Interval | 15 |
| State | MD |
| Symbol | RNAC |
| Target High Price | 44.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 33.66667 |
| Target Median Price | 38.5 |
| Total Cash | 147,606,000 |
| Total Cash Per Share | 4.879 |
| Total Debt | 63,853,000 |
| Total Revenue | 1,477,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.7026 |
| Two Hundred Day Average Change | -1.1226001 |
| Two Hundred Day Average Change Percent | -0.14574301 |
| Type Disp | Equity |
| Volume | 86,765 |
| Website | https://www.cartesiantherapeutics.com |
| Zip | 21,703 |